FDA approves BMS's (BMY.US) lung cancer drug repotrectinib.
According to reports, the FDA has approved the drug repotrectinib from Roche for the treatment of a type of non-small cell lung cancer.
According to reports, the FDA has approved Bristol-Myers Squibb's drug repotrectinib for the treatment of a type of non-small cell lung cancer. Media reported later on Wednesday that the drug has been approved. The agency accepted BMS's repotrectinib application in May. The pharmaceutical company is seeking approval for the use of the drug in the treatment of advanced or metastatic ROS1-positive non-small cell lung cancer. In 2022, BMS acquired Turning Point Therapeutics for $4.1 billion, thereby gaining access to the repotrectinib therapy.
Related Articles
Cinda: Global liquidity has tightened and the US dollar index may enter a period of wide fluctuations in the second half of the year.
Hong Kong Property: There were 79 second-hand public housing transactions registered in Hong Kong this month, representing a decrease of over 10% month-on-month.
Mei Wai: Affected by the adjustment of Hong Kong stocks, trading in the Hong Kong property market slowed down in June.
Cinda: Global liquidity has tightened and the US dollar index may enter a period of wide fluctuations in the second half of the year.
Hong Kong Property: There were 79 second-hand public housing transactions registered in Hong Kong this month, representing a decrease of over 10% month-on-month.
Mei Wai: Affected by the adjustment of Hong Kong stocks, trading in the Hong Kong property market slowed down in June.
RECOMMEND
